Skip to main content

Table 5 (abstract P411). Discrimination between patients on infliximab and placebo at week 12

From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three

  Infliximab mean change (SD) PBO mean change (SD) Guyatt’s effect size SMD
ASDAS 2.4 (1.3) 0.5 (0.6) 4.28 1.98
Physician’s global assessment, 0-10 mm VAS 5.2 (2.4) 1.6 (2.2) 2.34 1.56
JADAS27 (0-57) 12.7 (5.9) 4.3 (5.7) 2.22 1.46
JSpADA (0-8) 2.8 (1.2) 0.5 (1.4) 1.98 1.73
CRP (mg/L) 21.1 (8.4) 2.3 (10.9) 1.93 1.90
Total enthesitis (0-51) 8.5 (10.6) 1.6 (5.0) 1.71 0.85
Patient’s global assessment, 0-10 mm VAS 4.3 (3.8) 0.8 (2.8) 1.55 1.08
BASDAI total (0-10) 3.3 (3.1) 0.9 (2.3) 1.41 0.90
Active joint count (0-72) 4.4 (1.7) 2.6 (4.6) 0.96 0.51